Abstract
This randomized trial was performed to investigate the efficacy of low-dose rituximab in combination with glucocorticoids for treatment of patients with immune thrombocytopenia (ITP). Sixty-two patients were randomly separated into the glucocorticoids (control) and the experimental (glucocorticoids + rituximab) groups. Patients in both groups received dexamethasone 40 mg/day on days 1–4, followed by decrements of prednisone 60, 30, 15, 10 mg/day on days 5–7, 8–14, 15–21, 22–28, respectively. Patients in the experimental group also received rituximab 100 mg on days 7, 14, 21, 28. The overall response (OR) was similar in both groups at day 28 (experimental group vs. glucocorticoids group: 80.6 vs. 74.2%, P = .938); however, sustained response (SR) was more pronounced in the experimental group as compared to that in the glucocorticoids group (77.4 vs. 38.7%, P < .001). Both groups showed similar incidence of adverse events (experimental group vs. glucocorticoids group: 9.7 vs. 6.5%, P = .325). As expected, B cell depletion was seen in the experimental group. In addition, both groups experienced a significant up-regulation in Treg cell levels, but the up-regulation in the experimental group was maintained at an even higher level and persisted a longer time than those in the glucocorticoids group. Thus, low-dose rituximab combined with short-term glucocorticoids provides an alternative treatment for ITP prior to splenectomy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McMillan R. Immune-mediated thrombocytopenias: focus on chronic immune thrombocyto-penic purpura. Semin Hematol. 2007;44:1–2.
Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol Oncol Clin North Am. 2007;21:743–59.
Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112:1325–8.
Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–52.
Rodeghiero F, Ruggieri M. Is splenectomy still the gold standard for the treatment of chronic ITP? Am J Hematol. 2008;83:91.
Dolan JP, Sheppard BC, Deloughery TG. Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century. Am J Hematol. 2008;83:93–6.
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–33.
Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9:10–25.
Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25–33.
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immuneglobulin. N Engl J Med. 2006;355:1772–9.
Bruserud Q, Havardstein K. Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report. Hematology. 2009;14:224–6.
Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg) beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009;158:23–33.
Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115:2755–62.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Amold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.
Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, et al. Low dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93:930–3.
Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109:1401–7.
Guidry JA, George JN, Vesely SK, Kennison SM, Terrell DR. Corticosteroid side effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol. 2009;83:175–82.
Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141:149–69.
Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26:66–73.
Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell. 2007;130:25–35.
Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112:1147–50.
Kelly K, Glesson M, Murphy PT. Slow responses to standard dose rituximab in immune thrombocytopenic purpura. Haematologica. 2009;94:443–4.
Author information
Authors and Affiliations
Corresponding author
Additional information
Z. Li and W. Mou contributed equally to this work.
About this article
Cite this article
Li, Z., Mou, W., Lu, G. et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol 93, 91–98 (2011). https://doi.org/10.1007/s12185-010-0753-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-010-0753-z